$0.87—Stale · unknown old
NASDAQ • Last print unknown ago
$0.87—Stale · unknown old
Orphazyme A/S is a biotechnology company focused on developing treatments for rare diseases, particularly those involving protein misfolding disorders. Its lead product candidate, arimoclomol, targets Niemann-Pick disease type C, which has a significant unmet medical need in the U.S. and Europe.
Orphazyme generates revenue primarily through the commercialization of arimoclomol, leveraging its unique mechanism of action to address rare diseases. The company benefits from a niche market with limited competition, allowing for premium pricing and potential partnerships with larger pharmaceutical firms.
FDA approval status of arimoclomol
Partnership announcements with larger pharmaceutical companies
Clinical trial results for pipeline candidates
Market adoption rates of arimoclomol post-launch
Regulatory changes impacting drug approval processes
Technological advancements in competing therapies
Emerging therapies targeting the same indications
Potential for larger pharmaceutical companies to enter the rare disease space
Liquidity risk due to reliance on equity financing for R&D
Potential dilution from future capital raises
low - The demand for rare disease treatments is less correlated with the economic cycle, as these conditions require ongoing care regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for future financing needs, impacting R&D investment and operational flexibility.
minimal - The company currently has no debt, reducing credit risk.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock has historically exhibited high volatility due to binary outcomes related to clinical trials and regulatory approvals.